Victrex’s (VCT) “Add” Rating Reiterated at Peel Hunt
Other equities research analysts have also issued reports about the stock. UBS Group reissued a buy rating and issued a GBX 3,600 ($47.04) target price (up from GBX 3,300 ($43.12)) on shares of Victrex in a report on Thursday, October 4th. Liberum Capital reissued a buy rating on shares of Victrex in a report on Tuesday, October 16th. Finally, Morgan Stanley lowered shares of Victrex to an underweight rating and reduced their target price for the stock from GBX 2,500 ($32.67) to GBX 2,300 ($30.05) in a report on Friday, October 12th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of GBX 2,527.73 ($33.03).
Victrex stock opened at GBX 2,348 ($30.68) on Tuesday. Victrex has a 12-month low of GBX 1,826 ($23.86) and a 12-month high of GBX 2,772 ($36.22).
In related news, insider Richard Armitage acquired 1,010 shares of the business’s stock in a transaction on Wednesday, December 5th. The stock was acquired at an average cost of GBX 2,318 ($30.29) per share, with a total value of £23,411.80 ($30,591.66). Over the last ninety days, insiders have acquired 1,019 shares of company stock valued at $2,367,396.
Victrex Company Profile
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
Read More: What is a Fiduciary?
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.